Atlantic Equities Maintains Overweight on Bristol-Myers Squibb, Lowers Price Target to $85
Portfolio Pulse from richadhand@benzinga.com
Atlantic Equities analyst Steve Chesney maintains an Overweight rating on Bristol-Myers Squibb (NYSE:BMY) but lowers the price target from $90 to $85.
July 28, 2023 | 10:24 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target, Atlantic Equities maintains an Overweight rating on Bristol-Myers Squibb, indicating a positive outlook.
The lowered price target might initially seem negative, but the maintained Overweight rating indicates that the analyst still sees the stock as a good investment. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100